August 1, 1999Lara D. Veeken
Interpreting the clinical significance of the differential inhibition of cyclooxygenase-1 and cyclooxygenase-2
Population
17 international experts in arthritis, gastroenterology and pharmacology
Design
Guideline
Authors
Discussion
Loading...
Member takes
Implication
Standardizes COX-2 inhibitor classification for prescribing decisions; extends evidence by defining criteria for consistent in vitro and in vivo assessment.
Key Points
- To establish a formal consensus definition of COX-2 specificity and evaluate the biological and clinical relevance of differential COX-1 and COX-2 inhibition.
- Convened 17 international specialists across arthritis, gastroenterology, and pharmacology during the International Consensus Meeting on the Mode of Action of COX-2 Inhibition in December 1997.
- Reviewed biological mechanisms of COX-1 and COX-2, existing clinical trial data on selective inhibitors, and current methodologies for in vitro and in vivo assessment.
- Defined COX-2-specific agents as drugs that selectively block COX-2 without producing any inhibitory effect on COX-1 across their entire therapeutic dose range.
- Identified an absence of standardized guidelines for testing COX specificity in vitro and in vivo, highlighting the necessity of clear testing criteria to evaluate drug safety.
Structured PICO
P
Population
17 international experts in arthritis, gastroenterology and pharmacology
I
Intervention
COX-2-specific inhibitors
O
Outcome
Consensus definition of COX-2 specificity
This consensus meeting provided a definition for COX-2 specificity to guide in vitro and in vivo assessment of these agents.
Cite This Study
Brooks et al. (1999) studied this question.